# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K091361   
B. Purpose for Submission: Substantial equivalence determination for the Immulite 2000 test system   
C. Measurand: To detect antibodies to Treponema pallidum (T. pallidum)   
D. Type of Test: A solid phase, one-step chemiluminescent immunoassay   
E. Applicant: Siemens Healthcare Diagnostics, Inc.   
F. Proprietary and Established Names: Immulite $\textsuperscript { \textregistered }$ 2000 Syphilis Screen test system

# G. Regulatory Information:

Regulation section: 21 CFR $\ S$ 866.3830, Treponema pallidum treponemal test reagents

2. Classification: Class II

3. Product code: LIP - Enzyme linked immunoabsorption assay, Treponema pallidum

4. Panel:

Microbiology (83)

# H. Intended Use:

1. Intended use:

The Immulite 2000 syphilis screen test is a treponemal testing procedure for the qualitative detection of antibodies to Treponema pallidum in human serum or heparinized plasma on the Immulite 2000 analyzer as an aid in the diagnosis of syphilis. The Immulite 2000 syphilis screen is not intended for use in screening blood or plasma donors.

# 2. Indications for use:

The Immulite 2000 syphilis screen test is a treponemal testing procedure for the qualitative detection of antibodies to Treponema pallidum in human serum or heparinized plasma on the Immulite 2000 analyzer as an aid in the diagnosis of syphilis. The Immulite 2000 syphilis screen is not intended for use in screening blood or plasma donors.

3. Special condition for use statement: For prescription use only.

4. Special instrument requirements: Immulite 2000 Random Access Analyzer.

# I. Device Description:

The device is a kit consisting of a bead pack of 200 beads coated with purified recombinant T. pallidum 17 antigen (Tp17); a syphilis screen reagent wedge consisting of $1 1 . 5 \mathrm { m l }$ . of alkaline phosphatase conjugated to purified recombinant Tp 17 antigen; a syphilis screen adjustor consisting of one vial of lyophilized human serum with antibodies reactive to T. pallidum and syphilis screen controls – positive and negative . Kit components supplied separately include a chemiluminescent substrate, a probe wash, a probe cleaning kit and disposable reaction tubes.

# J. Substantial Equivalence Information:

1. Predicate device name:

DiaSorin Liaison $\textsuperscript { \textregistered }$ Treponema Assay

2. Predicate 510(k) number:

K061247

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Immulite 2000Syphilis screen test is atreponemal testingprocedure for thequalitative detection ofantibodies to Treponemapallidum in humanserum or heparinizedplasma</td><td rowspan=1 colspan=1>The LIAISONTreponema assay useschemiluminescentimmunoassaytechnology for thequalitative detection oftotal antibodies directedagainst Treponemapallidum in humanserum</td></tr><tr><td rowspan=1 colspan=1>Assay type</td><td rowspan=1 colspan=1>Enzyme labeled, onestep chemiluminescentimmunoassay</td><td rowspan=1 colspan=1>One step sandwichchemiluminescentimmunoassay</td></tr><tr><td rowspan=1 colspan=1>Cut-Offs</td><td rowspan=1 colspan=1>≥ 1.1 Reactive0.9 to &lt;1.1Indeterminate&lt; 0.9 non-reactive</td><td rowspan=1 colspan=1>≥ 1.1 Positive0.9 to &lt; 1.1 equivocal&lt; 0.9 negative</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>100μl</td><td rowspan=1 colspan=1>220 μl</td></tr><tr><td rowspan=1 colspan=1>Capture detectionAntigen/Antibody</td><td rowspan=1 colspan=1>Beads coated withpurified recombinantTreponema pallidump17 (TpN17) antigensare linked to enzymeconjugated purifiedrecombinant T.pallidum p17 antigenin the reagent</td><td rowspan=1 colspan=1>Magnetic particlescoated with Tp17DNA recombinantprotein specific for T.pallidum are linked toan isoluminol antigenconjugate</td></tr></table>

# K. Standard/Guidance Document Referenced:

CLSI – EP 07-A2 : Interference testing in Clinical Chemistry   
CLSI – EP 05: Evaluation of Precision Performance of Quantitative   
Measurement Methods   
CLSI C28-A3: Defining, Establishing and Verifying Reference Intervals in   
the Clinical Laboratory

# L. Test Principle:

Immulite 2000 Syphilis Screen is a solid-phase, one-step chemiluminescent enzyme immunoassay. The solid phase (beads) is coated with purified recombinant Treponema pallidum p17 (Tp17) antigen. The liquid phase consists of alkaline phosphatase (bovine calf intestine) conjugated to purified recombinant Treponema pallidum p17 (Tp17) antigen.

Patient sample and the reagent are incubated together with the coated beads for 30 minutes. During this time, total antibody to Treponema pallidum in the sample forms the antigen sandwich complex with purified recombinant Treponema pallidum p17 (Tp17) antigen on the bead and enzyme conjugated purified recombinant Treponema pallidum p17 (Tp17) antigen in the reagent. Unbound patient sample and enzyme conjugate are then removed by centrifugal washes. Finally, chemiluminescent substrate is added to the reaction tube containing the bead and the signal is generated in proportion to the bound enzyme.

# M. Performance Characteristics:

1. Analytical performance:

a. Precision/Reproducibility:

Reproducibility testing was performed using two different reagent lots at all testing sites for five days, twice each day. There were 4 replicates of each sample, quality control materials that are routinely provided with the kit (positive / negative controls) and 5 endogenous samples (low negative, high negative, low positive, high positive, and a sample around the cutoff) from pooled serum. Additionally, the assay adjustor was run as an unknown. This resulted in a yield of 40 replicates of each sample per lot at each site. Reproducibility of the Immulite syphilis screen as measured by between-site CV ranged from $7 . 1 \ \%$ to $2 2 . 6 \%$ for Lot 1 and from $6 . 1 \%$ to $2 9 . 7 \%$ for Lot 2.

b. Linearity/assay reportable range: Not applicable.   
c. Traceability, Stability, Expected values (controls, calibrators, or   
methods): Not applicable.

# d. Detection limit:

The Master Cutoff of the assay was determined from representative samples to achieve optimal sensitivity and specificity for the assay. The cutoff is set equal to the average counts per second of the Adjustor multiplied by the Curve Parameter 1. The result for a sample is reported as “Reactive” if the sample’s counts are above the indeterminate range, and “Nonreactive” if below this range. The result is reported as “Indeterminate” if the counts per sec. for that sample fall within $\pm 1 0 \%$ of the cut off.

# e. Analytical specificity:

Interference Study: Interference testing was conducted using serum and plasma per CLSI EP7A, Interference Testing in Clinical Chemistry. The following results were obtained:

o Hemoglobin: No effect was observed up to $5 9 2 . 6 \mathrm { m g / d L }$ of hemoglobin;   
o Bilirubin: no effect was observed up to $2 0 \mathrm { m g / d L }$ of conjugated or unconjugated bilirubin; Triglycerides: No effect was observed up to $3 0 0 0 \mathrm { m g / d L }$ of triglycerides.

Cross-Reactivity Study: To test for possible cross-reactivity, multiple patient samples containing different concentrations of potentially crossreactive antibodies were analyzed with the Immulite 2000 Syphilis Screen test.

<table><tr><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Total #Samples</td><td rowspan=1 colspan=1># Reactive/Total # Samples</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1/10</td></tr><tr><td rowspan=1 colspan=1>Epstein-Barr Virus</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1/10</td></tr><tr><td rowspan=1 colspan=1>Anti-Nuclear Antibodies</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1>Herpes Simplex Virus IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1/10</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1/10</td></tr><tr><td rowspan=1 colspan=1>Toxoplasma IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (anti-Fc)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1>Borrelia burgdorferi IgG(US strain)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2/10</td></tr><tr><td rowspan=1 colspan=1>Borrelia burgdorferi IgG (European strain)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1>Borrelia burgdorferi IgM (European strain)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1>Anti-Hepatitis B Surface Antigen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1/10</td></tr><tr><td rowspan=1 colspan=1>Hepatitis C Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5/20</td></tr><tr><td rowspan=1 colspan=1>Hepatitis B Surface Antigen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0/10</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>TOTALS</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>12 / 140</td></tr></table>

Twelve of the 140 samples tested yielded reactive results with the Immulite 2000 Syphilis Screen assay. These 12 samples were further tested with a commercially available blot assay and were verified as positive for the presence of antibody to T. pallidum.

# f. Assay cut-off:

Test value $=$ ratio of signal from sample to that of signal of adjustor curve parameter P1.

$\geq 1 . 1$ Reactive 0.9 to $< 1 . 1$ Indeterminate $< 0 . 9$ non reactive

2. Comparison studies:

# a. Method Comparison with Predicate:

An in-house study was conducted in order to compare Immulite Syphilis Screen product to a commercially available Treponema Assay. A total of 280 samples from various patient populations were tested, with the results summarized in the following tables.

# In-House Method Comparison, Lot 101

Table 18.7-2: Method Comparison Values   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>Commercially AvailableTreponema Assay</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=2 colspan=1>IMMULITE</td><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>54</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>226</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>280</td></tr></table>

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total Agreement</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>278/280</td></tr><tr><td rowspan=1 colspan=1>Positive Agreement</td><td rowspan=1 colspan=1>96.4%</td><td rowspan=1 colspan=1>54/56</td></tr><tr><td rowspan=1 colspan=1>Negative Agreement</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>224/224</td></tr></table>

There were two samples that were nonreactive with the Immulite 2000 assay but positive with the predicate assay. These samples were further tested with another Treponema Assay and both were negative by this assay.

# b. Matrix comparison:

Alternate Sample Types

In order to assess the effect of alternate sample types, blood was collected from 88 volunteers into plain, heparin, EDTA and Becton Dickinson $\mathbf { S S T } ( \mathbf { \mathbb { R } } )$ Vacutainer tubes. Forty eight of 88 samples were spiked with antibodies positive to T. pallidum to obtain positive and cut-off levels. All samples were assayed by the Immulite 2000 Syphilis Screen assay. The results were subjected to linear regression analysis.

Table 18.5: Alternate Sample Types   

<table><tr><td rowspan=1 colspan=1>TubeType</td><td rowspan=1 colspan=1>MeanRatio</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>3.29</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>Not Applicable</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>SST</td><td rowspan=1 colspan=1>3.09</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>(SST) = 0.91 (Plain tubes) + 0.105</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>3.65</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>(Heparin) = 1.06 (Serum) + 0.172</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>2.76</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>(EDTA) = 0.78 (Serum) - 0.027</td><td rowspan=1 colspan=1>0.97</td></tr></table>

It was determined that although heparinized plasma may increase values at or near the cutoff level, heparinized plasma is an acceptable sample type. EDTA plasma, however, is not recommended as a sample type and this is stated in the Limitations section of the package insert.

3. Clinical Studies:

# a. Clinical Sensitivity:

Clinical studies were conducted at three external sites in California, Virginia and The Netherlands using the Immulite 2000 Syphilis Screen. A total of 1286 serum samples were collected and tested in the study. The study subjects ranged in age from $< 1 8$ years– $6 5 +$ years, and $56 \%$ were male.

A method comparison study was performed comparing the IMMULITE 2000 Syphilis Screen method to results from a commercially available assay.

Medically Diagnosed Syphilis Patients   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Liaison Treponema Assay</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Immulite Syphilis Assay</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>273</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>272</td><td rowspan=1 colspan=1>281</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% Confidence Interval</td></tr><tr><td rowspan=1 colspan=1>Positive Agreement:</td><td rowspan=1 colspan=1>270/272=99.3%</td><td rowspan=1 colspan=1>97.4% - 99.9%</td></tr><tr><td rowspan=1 colspan=1>Negative Agreement:</td><td rowspan=1 colspan=1>6/8=75%</td><td rowspan=1 colspan=1>34.9% - 96.8%</td></tr><tr><td rowspan=1 colspan=1>Overall Agreement:</td><td rowspan=1 colspan=1>276/281=98.2%</td><td rowspan=1 colspan=1>95.9% - 99.4%</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Samples Sent for Routine Syphilis Testing</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Liaison Treponema Assay</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Immulite Syphilis Assay</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Non-Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>558</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>558</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>364</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>563</td><td rowspan=1 colspan=1>361</td><td rowspan=1 colspan=1>924</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% Confidence Interval</td></tr><tr><td rowspan=1 colspan=1>Positive Agreement:</td><td rowspan=1 colspan=1>359/361=99.4%</td><td rowspan=1 colspan=1>98.0% - 99.9%</td></tr><tr><td rowspan=1 colspan=1>Negative Agreement:</td><td rowspan=1 colspan=1>558/563=99.1%</td><td rowspan=1 colspan=1>97.9% - 99.7%</td></tr><tr><td rowspan=1 colspan=1>Overall Agreement:</td><td rowspan=1 colspan=1>917/924=99.2%</td><td rowspan=1 colspan=1>98.4% - 99.7%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>HIV Positive Samples</td><td rowspan=1 colspan=4></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Liaison Treponema Assay</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Immulite Syphilis Assay</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Non-Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>152</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>260</td><td rowspan=1 colspan=1>267</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>420</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% Confidence Interval</td></tr><tr><td rowspan=1 colspan=1>Positive Agreement:</td><td rowspan=1 colspan=1>260/261=99.6%</td><td rowspan=1 colspan=1>97.9% - 100%</td></tr><tr><td rowspan=1 colspan=1>Negative Agreement:</td><td rowspan=1 colspan=1>152/159=95.6%</td><td rowspan=1 colspan=1>91.1% - 98.2%</td></tr><tr><td rowspan=1 colspan=1>Overall Agreement:</td><td rowspan=1 colspan=1>412/420=98.1%</td><td rowspan=1 colspan=1>96.3% - 99.2%</td></tr></table>

# b. Clinical Specificity

See section M.3.a

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

4. Clinical cut-off:

Not applicable

# 5. Expected Values/Reference Range:

Serum samples from 157 apparently healthy male and female volunteers were tested by the Immulite 2000 syphilis screen assay. These samples yielded a mean value of 0.12, a median value of 0.09 and a $9 5 ^ { \mathrm { t h } }$ percentile of 1.12. Results are expressed as a signal to cut off ratio

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.